Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca receives approval for new gout therapy Zurampic

AstraZeneca receives approval for new gout therapy Zurampic

19th February 2016

AstraZeneca has announced that its drug Zurampic has been approved for the treatment of gout in the EU.

The European Commission has granted marketing authorisation for Zurampic to be used in combination with a xanthine oxidase inhibitor for the adjunctive treatment of hyperuricaemia in adult gout patients who have not achieved target serum uric acid levels.

This selective uric acid reabsorption inhibitor works by blocking the urate transporter responsible for the majority of the renal reabsorption of uric acid. As such, it is able to increase uric acid excretion and lower serum uric acid levels.

Sean Bohen, executive vice-president for global medicines development and chief medical officer at AstraZeneca, said: "We are pleased to offer a new treatment option for the many patients who are suffering from the effects of gout, and who are not reaching the recommended serum uric acid treatment targets with the current standard of care."

The approval was based on the positive findings of three pivotal phase III studies, CLEAR1, CLEAR2 and CRYSTAL, which represent the largest clinical trial data set of gout patients treated with combination urate lowering therapy.ADNFCR-8000103-ID-801812967-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.